Autologous Transplants for Multiple Myeloma: Updates from the 2008 American Society of Hematology Meeting

An Update of Treatments for Multiple Myeloma: Results from the 2006 American Society of Hematology Meeting

What is New in Multiple Myeloma? - Update From ASH 2005

Pesticides Linked to Monoclonal Gammopathy of Undetermined Significance (MGUS) (7/1/2009)
Researchers from the National Cancer Institute have reported that individuals who apply pesticides to crops are twice as likely as the general population to develop monoclonal gammopathy of undetermined significance (MGUS), which can lead to multiple myeloma. The details of this study appeared in the June 18, 2009 issue of Blood.

Formaldehyde Exposure May Increase Risk of Blood and Lymphatic Cancers (6/25/2009)
Researchers from the National Cancer Institute have reported that industrial workers who are exposed to formaldehyde may be at an increased risk of dying from blood and lymphohematopoietic malignancies, particularly myeloid leukemia but also Hodgkin’s lymphoma and multiple myeloma, according to the results of a study published in the Journal of the National Cancer Institute.

Mozobil™ Increases Autologous Peripheral Blood Stem Cell Harvests in Myeloma Patients (5/7/2009)
Researchers from several U.S. medical centers have reported that the addition of Mozobil® (plerixafor, AMD3100) to Neupogen® (filgrastim) significantly increases the efficiency of autologous peripheral blood stem cell harvests in patients with multiple myeloma. The details of this study appeared in an early online publication in Blood on April 10, 2009.

Thalidomid® Consolidation After Autologous Transplant Improves Outcomes in Myeloma (4/14/2009)
Researchers from Australia have reported that one year of low-dose Thalomid® (thalidomide) after a single autologous transplant prolongs survival of patients with multiple myeloma. The details of this study appeared in the April 10, 2009 issue of the Journal of Clinical Oncology.

Revlimid®-based Regimen with Neulasta® Support Very Effective for Relapsed Myeloma (3/18/2009)
Researchers affiliated with the German Myeloma Study Group have reported that a regimen of Revlimid® (lenalidomide), Adriamycin® (doxorubicin), and dexamethasone supported by Neulasta® (pegfilgrastim) resulted in a 74% complete or very good partial remission rate in patients with relapsed and refractory multiple myeloma. The details of this study appeared in an early online publication in Blood of January 30, 2009.